Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha Mitogen-Activated Protein Kinase Inhibitors
Hynes, J., Dyckman, A.J., Lin, S., Wrobleski, S.T., Wu, H., Gillooly, K.M., Kanner, S.B., Lonial, H., Loo, D., McIntyre, K.W., Pitt, S., Shen, D.R., Shuster, D.J., Yang, X., Zhang, R., Behnia, K., Zhang, H., Marathe, P.H., Doweyko, A.M., Tokarski, J.S., Sack, J.S., Pokross, M., Kiefer, S.E., Newitt, J.A., Barrish, J.C., Dodd, J., Schieven, G.L., Leftheris, K.(2008) J Med Chem 51: 4-16
- PubMed: 18072718 
- DOI: https://doi.org/10.1021/jm7009414
- Primary Citation of Related Structures:  
2RG5, 2RG6 - PubMed Abstract: 
A novel structural class of p38 mitogen-activated protein (MAP) kinase inhibitors consisting of substituted 4-(phenylamino)-pyrrolo[2,1- f][1,2,4]triazines has been discovered. An initial subdeck screen revealed that the oxindole-pyrrolo[2,1- f][1,2,4]triazine lead 2a displayed potent enzyme inhibition (IC 50 60 nM) and was active in a cell-based TNFalpha biosynthesis inhibition assay (IC 50 210 nM) ...